SLP Simulations Plus

Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its first quarter financial results for fiscal year 2020, the period ended November 30, 2019, after the close of the financial markets on Thursday, January 9, 2020.

The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on January 9, 2020. The live webcast/teleconference will be accessible by registering . Please dial in five to ten minutes prior to the scheduled start time. A live, listen-only webcast will also be available by dialing (914) 614-3221, and entering access code 601-658-992. A replay of the webcast will be available at the section of the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric for regulatory submissions and for drug-induced liver injury and . The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at .

Follow us on | |

EN
03/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Simulations Plus

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 9, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

 PRESS RELEASE

Simulations Plus and Enabling Technologies Consortium Announce Strateg...

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform. The collaboration focuses on enhancing the predictive capabiliti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch